Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 13/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1814786 | 0.93 | KDM4E (0.42) | ADORA1KDM4EHDAC9RORC | |
| SCHEMBL1810125 | 0.91 | KDM4E (0.42) | ADORA1KDM4EKMT2ARORCPOLB | |
| SCHEMBL1817001 | 0.87 | ADORA1 (0.48) | ADORA1ADORA2BKMT2APOLBADORA3 | |
| SCHEMBL1818962 | 0.85 | ADORA1 (0.42) | ADORA1KDM4EADORA2BKMT2APOLB | |
| SCHEMBL1815547 | 0.84 | KDM4E (0.42) | ADORA1KDM4EHDAC9KMT2ARORC | |
| SCHEMBL1809503 | 0.83 | ADORA1 (0.43) | ADORA1KDM4EADORA2BPOLBADORA3 | |
| SCHEMBL1817101 | 0.82 | SMN1; SMN2 (0.47) | KDM4EKMT2APOLB | |
| SCHEMBL1814347 | 0.81 | TAS2R14 (0.45) | ADORA1ADORA2BPOLB | |
| SCHEMBL1808088 | 0.80 | KMT2A (0.48) | ADORA1KDM4EKMT2APOLB | |
| SCHEMBL3299197 | 0.79 | ADORA1 (0.48) | ADORA1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321296-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-05-18 | — | — | EP | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| WO-2010020363-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | CYP3A5, ABAT, TPMT | ADORA1 724/4885KDM4E 2516/4885HDAC9 1882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.